New reports view cognitive dysfunction and chronic heart failure markets

The market for cognitive dysfunction - which encompasses several distinct disorders - will experience a dramatic overall sales increase, transforming the market from a meager $300.0 million in 2006 to $3.7 billion in 2016, driven by sales of new drugs from Myriad Genetics, Elan/Wyeth, Targacept/AstraZeneca and Memory Pharmaceuticals/Roche, according to research and advisory firm Decision Resources.

Four key cognitive dysfunctions are considered in the report-mild cognitive impairment, cognitive impairment associated with schizophrenia, cognitive dysfunction in multiple sclerosis and likewise the condition in traumatic brain injury.

The new Pharmacor report, entitled Cognitive Dysfunction, finds that the launch of new, expensive therapies over the next several years will boost diagnosis and drug treatment rates and propel a 12-fold increase in total sales, predominantly in the markets for mild cognitive impairment and this condition associated with schizophrenia. Myriad Genetics' Flurizan (tarenflurbil) and Elan/Wyeth's bapineuzumab - the first disease-modifying therapies for Alzheimer's will be prescribed off-label in mild cognitive impairment, driving an impressive 56% annual sales growth between 2011 and 2016.